You are here
- Home
- Therapy Areas
- Oncology/Infection
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- I
- Start Date
- Feb 9, 2011
- Study Name
- D4280C00010
- Study Id
- D4280C00010
- ClinicalTrials.gov ID
- NCT01291602
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
